Chronic kidney disease and the public health: Gaps in evidence from interventional trials

JAMA

Volumn 297, Issue 23, 2007, Pages 2630-2633

  Himmelfarb, Jonathan ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIALYSIS; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; INCIDENCE; INTERVENTION STUDY; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NOTE; PERFORMANCE MEASUREMENT SYSTEM; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; UREA BLOOD LEVEL; ARTICLE; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COST OF ILLNESS; HUMAN; KIDNEY DISEASE; PUBLIC HEALTH;

CHRONIC DISEASE; CLINICAL TRIALS; COST OF ILLNESS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES; PUBLIC HEALTH;

EID: 34250678023     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.23.2630     Document Type: Note

References (25)

1. Schoolwerth AC, Engelgau MM, Hostetter TH, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3:A57.
2. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol. 2005;16:3736-3741.
3. McClellan W, Speckman R, McClure L, et al. Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study. J Am Soc Nephrol. 2007;18:1344-1352.
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169.
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
6. Shlipak M, Stehman-Breen C. Observational research databases in renal disease. J Am Soc Nephrol. 2005;16:3477-3484.
7. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004;15:411-419.
8. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70:2021-2030.
9. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377-1384.
10. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218-228.
11. Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet. 2006;367:1319-1327.
12. Himmelfarb J, Kliger A. End-stage renal disease measures of quality. Annu Rev Med. 2007;58:387-399.
13. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med. 2006;145:512-519.
14. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010-2019.
15. Greene T, Daugirdas J, Depner T, et al. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias." J Am Soc Nephrol. 2005;16:3371-3380.
16. Porter ME, Teisberg EO. How physicians can change the future of health care. JAMA. 2007;297:1103-1111.
17. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int. 2007;71:312-317.
18. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcome. J Am Soc Nephrol. 1996;7:198-207.
19. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13:1307-1320.
20. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.
21. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
22. Coyne DW. Use of epoetin in chronic renal failure. JAMA. 2007;297:1713-1716.
23. Califf RM, Harrington RA, Madre LK, Peterson ED, Roth D, Schulman KA. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. Health Aff (Millwood). 2007;26:62-74.
24. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-1295.
25. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632.